Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
20.45
-1.15 (-5.32%)
Sep 23, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Revenue
Denali Therapeutics had revenue of $3.60M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $3.60M.
Revenue (ttm)
$3.60M
Revenue Growth
n/a
P/S Ratio
905.24
Revenue / Employee
$7,108
Employees
507
Market Cap
3.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Tarsus Pharmaceuticals | 606.33M |
| Arcutis Biotherapeutics | 463.98M |
| Zai Lab | 449.61M |
| Arcus Biosciences | 117.00M |
| Precigen | 85.72M |
| uniQure | 18.67M |
| Celldex Therapeutics | 158.00K |
DNLI News
- 9 days ago - Denali Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 14 days ago - Denali Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 22 days ago - Denali Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Denali Therapeutics price target raised to $35 from $30 at B. Riley - TheFly
- 6 weeks ago - Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley - TheFly
- 6 weeks ago - Denali Therapeutics price target raised to $34 from $25 at UBS - TheFly
- 6 weeks ago - Denali Therapeutics price target raised to $34 from $31 at Baird - TheFly
- 6 weeks ago - Denali Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts